Since the first scientific breakthroughs in advanced genetic and cell therapy, growth of the market has been inhibited by several important factors. But today:
MedXCell Science is currently raising capital in a Series B roundtable. It is a unique opportunity for investors to participate to the development of promising company with an ongoing phase 2 clinical trial and a full pipeline of products in a cutting edge industry. If you would like to know more and request access to MedXCell Science’s data room, please contact us.